From hddod onFlickr
Sounds ominous, no?
Symphogen and Origen announced a collaboration to develop a transgenic chicken capable of producing human antibodies against a wide variety of disease targets. Origen will use its avian transgenic technology to develop transgenic chickens, which can be immunized with any disease target of interest, including diseases such as cancer and autoimmunity. Symphogen will apply its antibody discovery and expression platforms to create novel, recombinant fully human monoclonal and polyclonal antibody therapeutics against such targets. Both companies plan to employ the jointly developed transgenic technology to produce novel antibody therapeutics.
Under the terms of the agreement, both companies will provide funding for the development of transgenic, human antibody-expressing chickens using Origen’s avian transgenic technology. Origen will receive upfront license payments and further payments upon reaching defined research and development goals. In addition, Symphogen and Origen will pay each other royalties on products arising from the technology. Once human antibody-producing chickens are developed (in which will no doubt be a wonderful day for humankind), both companies will hold rights to develop products from those birds. Furthermore, Symphogen will have the right to purchase exclusive access to the collaboration technology for use to generate human recombinant antibody products. The two companies plan to address targets in the areas of infectious disease, cancer and autoimmune diseases.
Symphogen and Origen Collaborate to Produce Transgenic Chicken for Generation of Fully Human Antibody Therapeutics
(Via MarketWatch)
Theoretically Related Posts
Eben is a highly caffeinated business development associate at a small, cash sensitive pharmaceutical company somewhere in Massachusetts. He enjoys cliche-less banter, compartmentalization, non-equilibrium thermodynamics and NPV analysis. Agree or disagree with what he's posted? He encourages comments.
If one were so inclined, one could follow him at any of these fine web 2.0 establishments:
Feel free to leave a comment below. Eben loves comments. You may also subscribe to comments through this RSS Comments feed or trackback here.
Add New Comment
Thanks. Your comment is awaiting approval by a moderator.
Do you already have an account? Log in and claim this comment.
Add New Comment
Trackbacks
(Trackback URL)